NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron
Purpose Antiemetic guidelines recommend co-administration of targeted prophylactic medications inhibiting molecular pathways involved in emesis. NEPA is a fixed oral combination of a new NK1 receptor antagonist (RA), netupitant (NETU 300mg), and palonosetron (PALO 0.50 mg), a pharmacologically disti...
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Artículo |
| Lenguaje: | English |
| Publicado: |
2017
|
| Materias: | |
| Acceso en línea: | http://eprints.uanl.mx/14551/1/63.pdf |